GeneDx Hldgs Q4 Sales $58.10M Beat $55.43M Estimate
Portfolio Pulse from Benzinga Newsdesk
GeneDx Hldgs (NASDAQ:WGS) reported Q4 sales of $58.10M, surpassing the $55.43M estimate by 4.82%. However, this represents a 5.30% decrease from the $61.35M sales reported in the same period last year.
February 20, 2024 | 9:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
GeneDx Hldgs reported Q4 sales of $58.10M, exceeding estimates but showing a year-over-year decline.
While GeneDx Hldgs exceeded quarterly sales estimates, indicating a positive short-term outlook, the year-over-year decline in sales could temper investor enthusiasm. The mixed results suggest a neutral short-term impact on the stock price as investors weigh the beat against the sales decrease.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100